Company intelligence / Profile preview
Amylyx Pharmaceuticals
Cambridge, Massachusetts, United Statesamylyx.com ↗
- Ownership
- Public · AMLX
- Development stage
- Other
01
Overview
Amylyx had a marketed drug (AMX0035/Relyvrio/Albrioza) for ALS that was withdrawn in April 2024 after Phase 3 trial failed to show efficacy. Currently advancing multiple clinical programs including AMX0114 (Phase 1 for ALS with first participant dosed in April 2025) and avexitide (Phase 3-ready for PBH with FDA Breakthrough Therapy Designation)[2][7][9][10]
- Therapeutic areas
- EndocrinologyRare DiseasesNeurology
- Modalities
- Small moleculesantisense oligonucleotides (ASO)peptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Gubra (for development of novel long-acting GLP-1 receptor antagonist)
04
Financials
- Market cap
- $3.5B
- Total revenue
- $0
- Enterprise value
- $2.7B
Beyond the preview
Go deeper on Amylyx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amylyx Pharmaceuticals.